Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

 

LEXINGTON, MA. June 11, 2020 – Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide (NCT04237623).

The study will enroll patients with high risk hematologic malignancies who are the recipients of a haploidentical cell transplant. The trial will evaluate the effectiveness of Leukine compared to a matched ...

Continue Reading →
0